Silence Therapeutics (NASDAQ: SLN) recently received a number of ratings updates from brokerages and research firms: 10/21/2026 – Silence Therapeutics was downgraded by Chardan Capital from “strong-buy” to “hold”. 10/21/2026 – Silence Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $20.00 price target on the stock, down from $75.00. […]